Stockreport

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) [Yahoo! Finance]

Dermata Therapeutics, Inc.  (DRMA) 
PDF of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. [Read more]